ATE396726T1 - Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten - Google Patents
Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheitenInfo
- Publication number
- ATE396726T1 ATE396726T1 AT04734217T AT04734217T ATE396726T1 AT E396726 T1 ATE396726 T1 AT E396726T1 AT 04734217 T AT04734217 T AT 04734217T AT 04734217 T AT04734217 T AT 04734217T AT E396726 T1 ATE396726 T1 AT E396726T1
- Authority
- AT
- Austria
- Prior art keywords
- adenosine
- receptor
- treatment
- mediated diseases
- benzothiazole derivatives
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03012118 | 2003-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396726T1 true ATE396726T1 (de) | 2008-06-15 |
Family
ID=33442738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04734217T ATE396726T1 (de) | 2003-05-30 | 2004-05-21 | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7285548B2 (de) |
| EP (1) | EP1633355B1 (de) |
| JP (1) | JP4426572B2 (de) |
| KR (1) | KR100765566B1 (de) |
| CN (1) | CN1798558B (de) |
| AR (1) | AR044569A1 (de) |
| AT (1) | ATE396726T1 (de) |
| AU (1) | AU2004243481B2 (de) |
| BR (1) | BRPI0410878A (de) |
| CA (1) | CA2527174C (de) |
| CL (1) | CL2004001272A1 (de) |
| DE (1) | DE602004014138D1 (de) |
| DK (1) | DK1633355T3 (de) |
| ES (1) | ES2307015T3 (de) |
| HR (1) | HRP20080318T3 (de) |
| IL (1) | IL171769A (de) |
| MX (1) | MXPA05012772A (de) |
| MY (1) | MY138018A (de) |
| NO (1) | NO20055176L (de) |
| NZ (1) | NZ543372A (de) |
| PL (1) | PL1633355T3 (de) |
| PT (1) | PT1633355E (de) |
| RU (1) | RU2348629C2 (de) |
| SI (1) | SI1633355T1 (de) |
| TW (1) | TW200508230A (de) |
| WO (1) | WO2004105755A1 (de) |
| ZA (1) | ZA200509608B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2369256T3 (es) * | 2000-06-26 | 2011-11-28 | Helen Of Troy Limited | Sistema de lámpara recargable. |
| RU2381227C2 (ru) * | 2004-07-22 | 2010-02-10 | Ф. Хоффманн-Ля Рош Аг | Замещенные бензотиазолы |
| US8247609B2 (en) * | 2005-10-25 | 2012-08-21 | Pharamleads | Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors |
| GB0622826D0 (en) * | 2006-11-15 | 2006-12-27 | Acurepharma Ab | Novel amides acting on the adenosine receptors |
| WO2010140339A1 (ja) * | 2009-06-01 | 2010-12-09 | 武田薬品工業株式会社 | 複素環化合物 |
| CN104981238B (zh) | 2012-12-21 | 2019-05-31 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL153278A0 (en) * | 2000-06-21 | 2003-07-06 | Hoffmann La Roche | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
-
2004
- 2004-05-21 MX MXPA05012772A patent/MXPA05012772A/es active IP Right Grant
- 2004-05-21 DK DK04734217T patent/DK1633355T3/da active
- 2004-05-21 KR KR1020057022791A patent/KR100765566B1/ko active IP Right Grant
- 2004-05-21 JP JP2006508188A patent/JP4426572B2/ja not_active Expired - Fee Related
- 2004-05-21 RU RU2005141307/04A patent/RU2348629C2/ru not_active IP Right Cessation
- 2004-05-21 AU AU2004243481A patent/AU2004243481B2/en not_active Ceased
- 2004-05-21 ES ES04734217T patent/ES2307015T3/es not_active Expired - Lifetime
- 2004-05-21 CA CA2527174A patent/CA2527174C/en not_active Expired - Fee Related
- 2004-05-21 CN CN2004800148906A patent/CN1798558B/zh not_active Expired - Fee Related
- 2004-05-21 EP EP04734217A patent/EP1633355B1/de not_active Expired - Lifetime
- 2004-05-21 WO PCT/EP2004/005474 patent/WO2004105755A1/en active IP Right Grant
- 2004-05-21 AT AT04734217T patent/ATE396726T1/de active
- 2004-05-21 PL PL04734217T patent/PL1633355T3/pl unknown
- 2004-05-21 DE DE602004014138T patent/DE602004014138D1/de not_active Expired - Lifetime
- 2004-05-21 BR BRPI0410878-7A patent/BRPI0410878A/pt not_active Application Discontinuation
- 2004-05-21 SI SI200430752T patent/SI1633355T1/sl unknown
- 2004-05-21 PT PT04734217T patent/PT1633355E/pt unknown
- 2004-05-21 NZ NZ543372A patent/NZ543372A/en unknown
- 2004-05-26 US US10/854,059 patent/US7285548B2/en not_active Expired - Fee Related
- 2004-05-26 TW TW093114971A patent/TW200508230A/zh unknown
- 2004-05-26 CL CL200401272A patent/CL2004001272A1/es unknown
- 2004-05-27 MY MYPI20042036A patent/MY138018A/en unknown
- 2004-05-28 AR ARP040101840A patent/AR044569A1/es not_active Application Discontinuation
-
2005
- 2005-11-03 NO NO20055176A patent/NO20055176L/no unknown
- 2005-11-03 IL IL171769A patent/IL171769A/en active IP Right Grant
- 2005-11-28 ZA ZA200509608A patent/ZA200509608B/en unknown
-
2008
- 2008-07-02 HR HR20080318T patent/HRP20080318T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE448206T1 (de) | Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen | |
| ATE505472T1 (de) | Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen | |
| ATE389649T1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE502005007427D1 (de) | 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten | |
| EE05516B1 (et) | Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine | |
| IS8134A (is) | Píperasínafleiður og notkun þeirra til að meðhöndla tauga- og geðsjúkdóma | |
| NO20055204D0 (no) | Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi | |
| DE60223715D1 (de) | Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten | |
| ATE374204T1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
| ATE318821T1 (de) | Pyranoindazole und ihre verwendung in der glaukombehandlung | |
| DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
| NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
| DE60327254D1 (de) | Den getreideertrag erhöhendes gen und dessen nutzung | |
| DE602004019995D1 (de) | Verwendung von n-arylhydrazinderivaten für die bekämpfung von schädlingen in und an tieren | |
| IS6966A (is) | Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| NO20041214L (no) | Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer | |
| IS7444A (is) | Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum | |
| ATE396726T1 (de) | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten | |
| ITMI20010957A0 (it) | Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche | |
| EE200400074A (et) | Koostised ning nende kasutamine proliferatiivsetehaiguste raviks | |
| ATE353648T1 (de) | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten | |
| ATE388145T1 (de) | Imidazol-derivate und ihre verwendung in der behandlung von mglur5-rezeptor vermittelten krankheiten | |
| NO20043029L (no) | Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer | |
| NO20030811D0 (no) | Kromenonderivater og anvendelse derav til behandling av sykdommer i forbindelse med 5-HTA1-reseptorer og/eller dopamin-D2-reseptorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1633355 Country of ref document: EP |